CRIS Current Research Information System

CESCON, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.058
AS - Asia 24.266
EU - Europa 16.551
AF - Africa 1.467
SA - Sud America 1.417
OC - Oceania 56
Continente sconosciuto - Info sul continente non disponibili 10
Totale 68.825
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.633
VN - Vietnam 6.929
SG - Singapore 6.286
CN - Cina 5.175
IT - Italia 3.346
GB - Regno Unito 3.091
DE - Germania 2.320
HK - Hong Kong 1.946
SE - Svezia 1.649
NL - Olanda 1.519
IN - India 1.213
FR - Francia 1.047
BR - Brasile 1.006
RU - Federazione Russa 742
BD - Bangladesh 665
UA - Ucraina 588
IE - Irlanda 567
KR - Corea 470
FI - Finlandia 432
CI - Costa d'Avorio 386
JP - Giappone 382
ZA - Sudafrica 359
TG - Togo 273
CA - Canada 238
CH - Svizzera 225
EE - Estonia 215
SC - Seychelles 187
AR - Argentina 177
PH - Filippine 172
BG - Bulgaria 159
JO - Giordania 138
TH - Thailandia 128
ID - Indonesia 124
AT - Austria 112
NG - Nigeria 111
MX - Messico 98
BE - Belgio 94
ES - Italia 93
PL - Polonia 93
IQ - Iraq 91
TR - Turchia 90
EC - Ecuador 82
PK - Pakistan 75
TW - Taiwan 68
SA - Arabia Saudita 55
AU - Australia 49
UZ - Uzbekistan 45
RO - Romania 43
IR - Iran 40
CL - Cile 35
GR - Grecia 31
LT - Lituania 30
MY - Malesia 30
HR - Croazia 28
CO - Colombia 26
MA - Marocco 25
PE - Perù 25
VE - Venezuela 24
EG - Egitto 23
PY - Paraguay 23
MK - Macedonia 22
AE - Emirati Arabi Uniti 21
KE - Kenya 18
ET - Etiopia 16
TN - Tunisia 16
CR - Costa Rica 15
DZ - Algeria 15
JM - Giamaica 14
NP - Nepal 14
CZ - Repubblica Ceca 13
LB - Libano 13
RS - Serbia 13
DO - Repubblica Dominicana 12
PS - Palestinian Territory 12
UY - Uruguay 12
SK - Slovacchia (Repubblica Slovacca) 11
PT - Portogallo 10
AL - Albania 9
OM - Oman 9
AZ - Azerbaigian 8
DK - Danimarca 8
HN - Honduras 8
IL - Israele 8
PA - Panama 8
LK - Sri Lanka 7
GH - Ghana 6
GT - Guatemala 6
KH - Cambogia 6
NO - Norvegia 6
AM - Armenia 5
BH - Bahrain 5
HU - Ungheria 5
KZ - Kazakistan 5
LU - Lussemburgo 5
NZ - Nuova Zelanda 5
SI - Slovenia 5
SY - Repubblica araba siriana 5
TT - Trinidad e Tobago 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BA - Bosnia-Erzegovina 4
Totale 68.715
Salva come PNG Salva come JPEG
Città #
Singapore 4.356
Ashburn 2.697
Southend 2.595
Fairfield 2.420
Hong Kong 1.848
Chandler 1.715
Ho Chi Minh City 1.515
San Jose 1.290
Hanoi 1.220
Woodbridge 1.145
Dong Ket 1.094
Wilmington 954
Houston 949
Seattle 933
Santa Clara 898
Hefei 881
Cambridge 781
Princeton 737
Bologna 713
Kerkrade 651
Ann Arbor 623
Beijing 600
Los Angeles 581
Dublin 565
Boardman 557
Frankfurt am Main 489
Dallas 478
Lauterbourg 414
New York 386
Abidjan 385
Seoul 379
Helsinki 347
Council Bluffs 342
Eygelshoven 338
Jacksonville 329
Tokyo 316
Lomé 273
Westminster 270
Nanjing 268
Munich 245
Milan 243
Berlin 229
Padova 229
Da Nang 226
Haiphong 218
Buffalo 217
Bern 185
São Paulo 168
Sofia 155
Rome 146
Florence 141
Jinan 141
Redondo Beach 139
Saint Petersburg 134
Amman 131
Guangzhou 131
San Diego 131
Shenyang 129
Redmond 107
Delhi 100
Turin 98
Changsha 96
Shanghai 96
Chicago 93
Dearborn 93
Johannesburg 88
Nanchang 88
Phoenix 88
Hebei 87
Abeokuta 86
Brussels 86
Des Moines 86
Amsterdam 81
Medford 80
Bengaluru 79
Biên Hòa 78
London 77
Toronto 76
Bremen 73
The Dalles 72
Hải Dương 69
Zhengzhou 68
Can Tho 66
Montreal 66
Tianjin 66
Vienna 66
Orem 64
Mülheim 62
Falls Church 59
Jakarta 59
Falkenstein 58
Hyderabad 57
Brooklyn 56
Olalla 56
San Francisco 56
Nuremberg 54
Hangzhou 53
Thái Nguyên 52
Bangkok 50
Jiaxing 50
Totale 43.765
Salva come PNG Salva come JPEG
Nome #
[Angiogenic factors and their relation to stage, lymph-node micrometastases and prognosis in patients operated on for gastric cancer] 1.635
The histological assessment of liver fibrosis in grafts from extended criteria donors predicts the outcome after liver transplantation: A retrospective study 651
Hepatobiliary Scintigraphy in the Preoperative Evaluation of Potential Living Liver Donors 501
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts 417
Extracorporeal interval support for organ retrieval delivery regional experience with sharing equipe, equipment & expertise to increase conventionally defined as controlled donor pool in time of pandemic 383
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study 367
SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study 354
Appraisal of disease-specific benefits of minimally invasiveness in surgery of breast cancer liver metastases 352
Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study 344
TRAPIANTO DI FEGATO CON TROMBOSI PORTALE COMPLETA: ESPERIENZA DI 11 CASI TRATTATI MEDIANTE ANASTOMOSI TRA LA VENA PORTA DEL GRAFT E LA VARICE GASTRICA DEL RICEVENTE 330
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 328
Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study 321
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 317
A comprehensive analysis on expected years of life lost due to pancreatic cancer 310
Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome 302
Molecular Aging of Human Liver: An Epigenetic/Transcriptomic Signature 277
Hypothermic Oxygenated New Machine Perfusion System in Liver and Kidney Transplantation of Extended Criteria Donors:First Italian Clinical Trial 277
Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study 274
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 271
A new liver transplant priority for patients with hepatocellular carcinoma. 266
Identification of miR-31-5p, miR-141-3p, miR-200c-3p, and GLT1 as human liver aging markers sensitive to donor-recipient age-mismatch in transplants 265
Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. 262
Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation 262
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 261
Burnout and psychological distress between surgical and non-surgical residents 257
Comprehensive surgical intestinal rescue and transplantation program in adult patients: Bologna experience. 249
The Effect of a Liver Transplant Program on the Outcomes of Resectable Hepatocellular Carcinoma: A Nationwide Multicenter Analysis 247
Machine Learning Pipeline for the Automated Prediction of MicrovascularInvasion in HepatocellularCarcinomas 244
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 243
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 243
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis 242
Surgical therapy for hepatolithiasis: a Western experience. 240
Causes of early acute graft failure after liver transplantation: analysis of a 17-year single-centre experience. 239
Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma 238
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 236
Long-term outcomes after hypothermic oxygenated machine perfusion and transplantation of 1,202 donor livers in a real-world setting (HOPE-REAL study) 235
Hypothermic oxygenated perfusion in extended criteria donor liver transplantation-A randomized clinical trial 234
Use of perfusional angiosonography in liver transplantation and conservative management of post-transplant intra-hepatic pseudo-aneurysm. 233
Conventional split liver transplantation for two adult recipients: a recent experience in a single European center 233
Lifelong maintenance of composition, function and cellular/subcellular distribution of proteasomes in human liver 229
The peculiar aging of human liver: A geroscience perspective within transplant context 228
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 228
A matched pair analysis of multicenter longterm follow-up after split-liver transplantation with extended right grafts 227
LncRNAs as novel players in hepatocellular carcinoma recurrence 224
Bacterial translocation in adult small bowel transplantation 223
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. 222
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 222
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 221
Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments 221
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 219
Combined kidney-liver, heart-liver, and kidney-pancreas transplantations from a single deceased donor. 218
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma 218
Complex Liver Transplantation Using Venovenous Bypass With an Atypical Placement of the Portal Vein Cannula 218
Combined liver–dual kidney transplant: Role in expanded donors 216
Automatically extracted machine learning features from preoperative CT to early predict microvascular invasion in HCC: the role of the Zone of Transition (ZOT) 216
Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. 215
An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. 215
Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. 215
Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation:a management challenge 215
Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma (Scientific Reports (2017) 7 (44685) DOI: 10.1038/srep44685) 215
Associated benign liver tumors in idiopathic granulomatous hepatitis: a case report 214
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the MNGIE International Network 214
Acute cellular rejection monitoring after interstinal transplant: utility of serologic markers and zoom videoendoscopy as support of conventional biopsy and clinical findings. 213
Studies on immunoproteasome in human liver. Part I: absence in fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis 212
Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pre-transplant Radiology 212
Liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical long-term follow-up and pathogenic implications 212
Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. 211
Coping strategies in intestinal transplantation 211
Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation. 210
Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center 210
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 208
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 208
Pre-transplant psoas muscle density as a ready-to-use and low-cost predictor of patient survival after liver transplant 207
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 207
Anatomic variations of intrahepatic bile ducts in a European series and meta-analysis of the literature. 206
Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection. 204
Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases 204
The role of lymphadenectomy for liver tumors. Further considerations on the appropriateness of treatment strategy 203
Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. 203
Italian experience in adult clinical intestinal and multivisceral transplantation: 6 years later. 203
Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients. 202
Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period. 201
Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. 200
Assessment of donor steatosis in liver transplantation: is it possible without liver biopsy? 196
Combined heart-liver transplantation: A single-center experience 196
Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 196
Induction therapy with Alemtuzumab (Campath) in combined liver-kidney transplantation: University of Bologna experience. 195
In Reply 195
Psychological Adaptation and Quality of Life of Adult Intestinal Transplant Recipients: University of Bologna Experience 195
Impact of psychosocial status on liver transplant process 195
Efficacy of MELD score in predicting survival after liver retransplantation. 194
Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center 192
Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period. 192
Hypothermic oxygenated perfusion versus static cold storage for expanded criteria donors in liver and kidney transplantation: Protocol for a single-center randomized controlled trial 192
An uncommon focal liver lesion: Intrahepatic splenosis 192
Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients. 190
Assessment of perioperative transfusion requirement for cirrhotic patients undergoing elective hepatectomy 190
Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. 190
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. 189
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. 189
Totale 25.618
Salva come PNG Salva come JPEG
Categoria #
all - tutte 190.932
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 190.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.864 0 0 0 0 0 0 0 0 0 0 0 1.864
2021/20226.542 496 236 357 521 587 282 163 505 298 405 1.602 1.090
2022/20237.563 722 1.101 385 970 504 612 235 490 1.346 205 575 418
2023/20242.300 196 405 150 218 178 384 108 146 89 175 133 118
2024/20259.962 483 1.363 850 762 1.363 543 717 341 226 792 580 1.942
2025/202628.175 2.155 2.636 2.247 1.746 2.496 2.544 3.621 874 5.129 2.074 1.392 1.261
Totale 70.137